Autophagy as a Possible Mechanism of Resistance in pNET Treatment

#1111

Introduction: Pancreatic neuroendocrine tumor (pNET) patients often display primary or secondary resistance to Sunitinib, an anti-angiogenic multi-receptor tyrosine kinase inhibitor which has been approved for the treatment of late stage pNETs. In late cancer stage autophagy often has a tumor promoting role. Sunitinib might additionally activate autophagy through inhibition of mTOR or induction of hypoxia.

Aim(s): To assess whether autophagy acts as a mechanism of resistance in late stage pNETs and if autophagy inhibition increases therapy efficacy

Materials and methods:

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Wiedmer T, Marinoni I, Tschan M, Perren A,

Keywords: pNET, autophagy, Sunitinib, resistance,